#NATUS WEISSBLATT SOFTWARE#

It's currently valued at two times its cost of investment, making it a top decile performer for buyout funds launched in 2019, according to Preqin data. MP I closed on €1 billion in 2020 - at the time, a record for a European-based private equity healthcare fund. Since inception, ArchiMed has been a committed Impact investor, both directly and through its Eurêka Foundation.ĪrchiMed's mid-market buy-and-build fund, MED Platform II (MP II), is a successor to the fully invested MED Platform I (MP I). ArchiMed manages €5 billion across its various funds. Over the last twenty years, ArchiMed's leadership team has directly managed and invested in over eighty small- to large-size healthcare companies globally, representing over €50 billion of combined value. ArchiMed helps partners internationalize, acquire, innovate and expand their products and services.

#NATUS WEISSBLATT SOFTWARE#

Prioritized areas of focus include Biopharmaceutical Products & Services, Life Science Tools, Medical Devices & Technologies, Diagnostics, Health Technologies & Software and Consumer Health. Its mix of operational, medical, scientific and financial expertise allows ArchiMed to serve as both a strategic and financial partner to North American and European healthcare businesses. With sales in over 100 countries, Natus is a leader in neurodiagnostics, pediatric retinal imaging, and infant hearing screening, as well as a leading company in hearing assessment, hearing instrument fitting, balance, and intracranial pressure monitoring.Ībout ArchiMed - With offices in the US and Europe, ArchiMed is a leading investment firm focused exclusively on healthcare industries. The Company offers hardware, advanced software and algorithms, and consumables that provide stimulus, acquire and monitor physiological signals, and capture the body’s response. Jefferies served as financial advisor and Latham & Watkins LLP served as legal advisor to ArchiMed.Ībout Natus Medical Incorporated - Natus delivers innovative and trusted solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems to advance the standard of care and improve patient outcomes and quality of life. In connection with the transaction, Stifel served as financial advisor and Davis Polk & Wardwell LLP served as legal advisor to Natus.

“Austin's leadership at Natus has been vital to our advancement as a leading Neuroscience company and I am pleased to partner with him in this next phase of our growth,” stated Mr. Noll's exemplary career of over ten years of leadership at Natus. Noll III was promoted to President of Natus. In conjunction with the closing of the transaction, Natus Chief Commercial Officer Austin F.

“Together with management, we'll significantly expand the reach and breadth of Natus' market leading products, reinforce and focus research & development, and pursue acquisitions of complementary businesses,” says ArchiMed Partner Justin Bateman. “Our Natus Teammates are excited to advance the standard of care and improve outcomes and quality of life for patients affected by disorders of the brain, neural pathways, and eight sensory nervous systems as a part of ArchiMed.” Sullivan, Chief Executive Officer of Natus. “ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue our mission to serve our customers as we internationalize and grow our business,” said Thomas J. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. MIDDLETON, Wis., J(GLOBE NEWSWIRE) - Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed (“ArchiMed”), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus.

Natus weissblatt